Načítá se...

CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects

Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic treatments are available. Repurposing drugs that target α-synuclein aggregation, considered one of the main drivers of PD progression, could accelerate the development of disease-modifying therapies. In this wor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: González-Lizárraga, Florencia, Ploper, Diego, Ávila, César L., Socías, Sergio B., dos-Santos-Pereira, Mauricio, Machín, Belén, Del-Bel, Elaine, Michel, Patrick Pierre, Pietrasanta, Lía I., Raisman-Vozari, Rita, Chehín, Rosana
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7679368/
https://ncbi.nlm.nih.gov/pubmed/33219264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-76927-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!